These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 39058261)
1. Enhanced Omicron Variant Neutralization by a Human Antibody Tailored to Wild-Type and Delta-Variant SARS-CoV-2 RBDs. Lee J; Kim B; Woo HM; Kim JW; Jung I; Park SW; Kim YS; Na JH; Jung ST Mol Pharm; 2024 Sep; 21(9):4336-4346. PubMed ID: 39058261 [TBL] [Abstract][Full Text] [Related]
2. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-GuardeƱo JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142 [TBL] [Abstract][Full Text] [Related]
3. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X MAbs; 2021; 13(1):1953683. PubMed ID: 34313527 [TBL] [Abstract][Full Text] [Related]
4. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572 [TBL] [Abstract][Full Text] [Related]
5. Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain. Miller NL; Clark T; Raman R; Sasisekharan R Cell Rep Med; 2022 Feb; 3(2):100527. PubMed ID: 35233548 [TBL] [Abstract][Full Text] [Related]
7. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]
8. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194 [TBL] [Abstract][Full Text] [Related]
9. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668 [TBL] [Abstract][Full Text] [Related]
10. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823 [TBL] [Abstract][Full Text] [Related]
12. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510 [TBL] [Abstract][Full Text] [Related]
13. Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. Cheng L; Song S; Zhou B; Ge X; Yu J; Zhang M; Ju B; Zhang Z Virol J; 2021 Apr; 18(1):87. PubMed ID: 33910569 [TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283 [TBL] [Abstract][Full Text] [Related]
15. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection. Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290 [TBL] [Abstract][Full Text] [Related]
16. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260 [TBL] [Abstract][Full Text] [Related]
17. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related]
19. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Tai W; Zhang X; He Y; Jiang S; Du L Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117 [TBL] [Abstract][Full Text] [Related]